Angion Biomedica

Company

Investment-firm

Last deal

$117M

Amount

Post-IPO Equity

Stage

05.02.2021

Date

3

all rounds

$176.27M

Total amount

Financing round

General

About Company
Angion Biomedica is a clinical-stage biopharmaceutical company focused on restoring organs, with a particular focus on renal disease.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1998

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass. Additionally, Angion Biomedica is developing ANG-3777, a hepatocyte growth factor (HGF) mimetic, for multiple acute organ injuries and related indications, including acute kidney injury and injuries to other major organs such as the lungs, central nervous system, and heart. The company is also advancing multiple programs for the treatment of fibrotic diseases, with ANG-3070, a tyrosine kinase inhibitor and inhibitor of rho kinase 2, leading the way.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Adrenomed

Adrenomed

Adrenomed is a clinical-stage biopharmaceutical company that rescues vascular integrity to save critically ill patients.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Berlin, Germany

total rounds

7

total raised

$56.83M
BioAxone BioSciences

BioAxone BioSciences

BioAxone is a clinical-stage biopharmaceutical company that is revolutionizing treatments for neurotrauma and neurovascular disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boston, MA, USA
Amarin

Amarin

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving cardiovascular disease treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Ballsbridge, Dublin, Ireland

total rounds

4

total raised

$227.82M
BioLeaders

BioLeaders

BioLeaders is a clinical stage biopharmaceutical company that develops therapies to enhance the body's immune systems.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Yongin-si, Gyeonggi-do, South Korea

total rounds

1
M&A Details
1

Acquired by

Elicio Therapeutics

announced date

01.01.2023

Financials

Funding Rounds
7
3

Number of Funding Rounds

$176.27M

Money Raised

Their latest funding was raised on 05.02.2021. Their latest investor National Science Foundation. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Vifor Pharma

Vifor Pharma

Vifor Pharma Group is a global pharmaceutical company focused on innovative therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Pharmaceuticals, Health Care, Biotechnology

Location

Opfikon, Switzerland

count Of Investments

1
U.S. Department of Defense

U.S. Department of Defense

The U.S. Department of Defense provides military forces to deter war and protect national security.

Sector

Aerospace and Defense

Subsector

Defense

Keywords

Government, Security, Military

Location

Washington Cir NW, Washington, DC, USA

count Of Investments

198

count Of Exists

15
Investments
1
Date 
name 
Lead 
type 
Raised 
Elicio Therapeutics

Elicio Therapeutics

Elicio Therapeutics develops immuno-tumor vaccines to treat cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Cambridge, MA, USA

total rounds

18

total raised

$220.61M
Co-Investors
Investors
4
3

Number of lead investors

4

Number of investors

Investor 
Lead 
Round 
Partners 
National Science Foundation

National Science Foundation

The National Science Foundation (NSF) is an independent federal agency that funds scientific research and education in the United States.

Sector

Industrial Support Services

Subsector

Business Training and Employment Agencies

Keywords

Education

Location

Alexandria, VA, USA

count Of Investments

4514

count Of Exists

186
U.S. Department of Defense

U.S. Department of Defense

The U.S. Department of Defense provides military forces to deter war and protect national security.

Sector

Aerospace and Defense

Subsector

Defense

Keywords

Government, Security, Military

Location

Washington Cir NW, Washington, DC, USA

count Of Investments

198

count Of Exists

15
Vifor Pharma

Vifor Pharma

Vifor Pharma Group is a global pharmaceutical company focused on innovative therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Pharmaceuticals, Health Care, Biotechnology

Location

Opfikon, Switzerland

count Of Investments

1

People

Founders
1
Itzhak Goldberg
Itzhak Goldberg

Itzhak Goldberg

Itzhak Goldberg, MD, FACR, is Angion’s Founder and its past President and CEO. Previously, he was a faculty member at Harvard Medical School, Boston, Mass., Radiation Oncologist-in-Chief for the North Shore-Long Island Jewish Health System (now Northwell Health), New Hyde Park, NY, Professor at the Albert Einstein College of Medicine, Bronx, NY. He is a Fellow of the American College of Radiology. Prior to that, Dr. Goldberg was a Research Fellow and recipient of the William Milton Award at Harvard Medical School and a Research Affiliate at MIT. Dr. Goldberg has made seminal contributions in the area of hepatocyte growth factor signaling, apoptosis and angiogenesis, has published extensively in these areas and is an inventor on numerous patents.

current job

Angion Biomedica
Angion Biomedica

organization founded

1

Itzhak Goldberg

Employee Profiles
7

Joan Puchalski

Senior clinical trial manager

Jay Venkatesan

Jay Venkatesan

President, Chief Executive Officer and Director

Prakash Narayan

Chief operating officer

Latha Paka

Research scientist

Itzhak Goldberg

Itzhak Goldberg

Executive Chairman and Chief Scientific Officer

Activity

Recent News
0